Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The presence of the expression of oncoproteins c-erbB2 and EGFR, high index IP PCNA, Ki67 and low levels of steroids receptors correlates with high histological malignancy (Bloom III0); 2.
|
10840938 |
2000 |
Malignant Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
EGFR DNA methylation levels significantly increased (P < 0.05) following NSCLC malignancy upgrading, and showed negative correlation with mRNA expression (P = 0.041).
|
26505339 |
2015 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These data suggest that the concomitant modulation of Akt and ER stress pathways with the OSU-03012/EGFR inhibitor combination represents a unique approach to overcoming EGFR inhibitor resistance in NSCLC and perhaps other types of cancer with elevated basal Akt activities.
|
18413750 |
2008 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.
|
29616128 |
2018 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Activation of epidermal growth factor receptor (EGFR) has been reported in a variety of cancer types, including colorectal cancer (CRC), and represents a potential chemotherapeutic drug target.
|
31308698 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) occurs in non-small cell lung cancer (NSCLC) patients who initially respond to TKI treatment but whose cancer then progresses.
|
23916913 |
2013 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The introduction of KRAS testing as a diagnostic tool to select patients for epidermal growth factor receptor (EGFR)-targeted cetuximab- or panitumumab-based therapies for metastatic colorectal cancer is widely regarded as a key advance in the field of personalized cancer medicine.
|
20383783 |
2010 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Smart nanoparticles assembled by endogenous molecules for siRNA delivery and cancer therapy via CD44 and EGFR dual-targeting.
|
30352311 |
2019 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Furthermore, our data suggest that the effects of TACE on the malignancy of HeLa cells may be mediated via activation of the EGFR (epidermal growth factor receptor) signaling pathway.
|
18996214 |
2009 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
EGFR is overexpressed in a wide range of malignancies, including HNSCC, and initiates important signal transduction pathways in HNSCC carcinogenesis.
|
23821327 |
2013 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NRF2 and epidermal growth factor receptors (EGFRs/HERs) are regulators of cellular proliferation and determinants of cancer initiation and progression.
|
29410730 |
2017 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Overall, our systems biology modeling together with experimental validations reveals that inhibition of survival signals and concomitant release of apoptotic potential jointly contribute to the tumor cell death following the inhibition of addicted oncogene in EGFR addicted cancers.
|
22194952 |
2011 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
This is the first study performed on cancer patient material showing that chromosome 7 aneuploidy and high human papillomavirus 16 E6 mRNA expression lead to membrane epidermal growth factor receptor overexpression in cervical cancer.
|
21252859 |
2011 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Epidermal growth factor receptor (EGFR) is an important target for cancer therapy.
|
28630865 |
2017 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
<i>EGFR</i> mutations in cfDNA, both the activating mutation and <i>EGFR</i> T790M, became undetectable in most patients in the setting of clinical response and reemerged upon disease progression.<b>Conclusions:</b> ASP8273 was well tolerated and promoted antitumor activity in patients with <i>EGFR</i>-mutant lung cancer with disease progression on prior EGFR TKI therapy.<i>Clin Cancer Res; 23(24); 7467-73.©2017 AACR</i>.
|
28954786 |
2017 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The kinase domain of EGFR is highly conserved in whole gastric cancer cell lines and cases, therefore treatment with gefitinib is unfortunately not recommended for such malignancy.
|
16353180 |
2006 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, TF could serve as a therapeutic target in EGFR-dependent malignancies.
|
19074872 |
2008 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The human papillomavirus (HPV) E6 oncoprotein enhances the oncogenic potential of ErbB proteins in HPV-related malignancies.
|
28963790 |
2018 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In lung cancer cells, any EGFR ligand was not recognized as a validated target for cancer therapy.
|
18023415 |
2008 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our findings show that downmodulation of HER3 by EZN-3920 leads to the suppression of tumor growth in vitro and in vivo, suggesting that HER3 can be an effective target for the treatment of various cancers that have been activated by HER3 alone or where HER3 activation is associated with EGFR or HER2 expression.
|
23395887 |
2013 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The role of EGFR overexpression/mutation and new modulators of EGFR traffic in cancer and the response to cancer therapeutics are also discussed.
|
24295852 |
2014 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals.
|
31019378 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The transmembrane tyrosine kinases, including insulin‑like growth factor 1 receptor (IGF1R), vascular endothelial growth factor receptor (VEGFR) or epidermal growth factor receptor (EGFR) have been implicated in the survival and metastasis of cancer.
|
30226540 |
2018 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These results contribute to an improved understanding of the EGFR dimer stability and provide new elements for understanding the relationship between EGFR and cancer.
|
20049516 |
2010 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our results provide an example of EGFR deregulation in cancer through silencing of components of the nuclear import pathway.
|
29229958 |
2017 |